Developing mRNA influenza vaccines in the wake of COVID-19

Vaccine Insights 2023; 2(3), 27–32

DOI: 10.18609/vac.2023.006

Published: 16 March 2023
Raffael Nachbagauer

Charlotte Barker, Editor, Vaccine Insights, speaks to Raffael Nachbagauer, Program Leader and Executive Director of Infectious Disease Development at Moderna, about his work to improve seasonal influenza vaccinations with the help of mRNA technology

Raffael Nachbagauer oversees the influenza vaccine development portfolio at Moderna. Prior to joining Moderna, he was an Assistant Professor at the Icahn School of Medicine at Mount Sinai where his research focused on the immune responses to virus infections and vaccination, as well as the development of novel influenza vaccines.